MIM Software receives FDA clearance to market products running on tablets through thin client technology

Michael Walter | | Health Imaging | Medical Imaging

MIM Software announced this week it has received 510(k) clearance from the FDA. The company can now market its full product line running on tablets through thin client technology.

Jerimy Brockway, MIM vice president of engineering, said in a prepared statement that this makes using the company’s products much more convenient.

“Receiving 510(k) clearance gives MIM users the ability to access all of the technology and power of our leading products on a mobile device,” Jerimy Brockway, MIM vice president of engineering, said in a prepared statement. “This allows physicians to work on a patient case on the same software after they leave the office.”

MIM also announced that it will be demonstrating its product line from booth # 931 at the Society of Nuclear Medicine and Molecular Imaging 2016 Annual Meeting in San Diego, Calif., June 11-15. 

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

U.S. moves closer to establishing domestic supply of Mo-99 for nuclear imaging
RSNA 2024 Program Chair Kate Hanneman highlights key trends in radiology
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage
FDA says CT scans sometimes damage implantable cardiac electronic devices
Bilingual people have more efficient brains, imaging study shows
Use of AI opportunistic screening in CT for cardiovascular disease

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.